Crinetics Pharmaceuticals (CRNX) Equity Average (2018 - 2026)

Crinetics Pharmaceuticals' Equity Average history runs 9 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• In Q1 2026, Equity Average fell 11.87% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (down 11.87% YoY), while the FY2025 annual figure was $1.2 billion, up 24.3% from the prior year.
• Equity Average was $1.1 billion for Q1 2026 at Crinetics Pharmaceuticals, up from $1.0 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $1.3 billion in Q1 2025 to a low of $267.2 million in Q2 2023.
• Historically, Equity Average has averaged $714.0 million across 5 years, with a median of $707.0 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Equity Average dropped 22.46% in 2023, then jumped 219.15% in 2024.
• A 5-year view of Equity Average shows it stood at $333.8 million in 2022, then soared by 62.78% to $543.4 million in 2023, then soared by 98.53% to $1.1 billion in 2024, then dropped by 4.33% to $1.0 billion in 2025, then advanced by 10.1% to $1.1 billion in 2026.
• The last three Equity Average figures came in at $1.1 billion (Q1 2026), $1.0 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.